How to Reassess Risk Profiles During Product Lifecycle
As pharmaceutical products move from development to commercial distribution, their associated risk profiles evolve. Regulatory guidelines such as ICH Q9 and Q12 stress the importance of continuous risk reassessment across the product lifecycle. For stability programs, this means reevaluating earlier assumptions about degradation pathways, storage conditions, and shelf life based on emerging data and real-world…
Read More “How to Reassess Risk Profiles During Product Lifecycle” »